Meeting Overview - The second extraordinary general meeting of shareholders for East China Pharmaceutical Co., Ltd. is scheduled for December 9, 2025, at 14:00, located at the company's new building in Hangzhou, Zhejiang Province [3][4] - The meeting will utilize a combination of on-site and online voting methods, convened by the board of directors and presided over by the chairman, Lü Liang [4] Attendance Details - A total of 526 shareholders attended the meeting, representing 1,074,532,240 shares, which accounts for 61.2611% of the total voting shares [5] - Among them, 524 small shareholders participated, representing 55,594,083 shares, or 3.1695% of the total voting shares [5] Proposal Voting Results - The proposal to repurchase and cancel part of the restricted stock was approved with 1,074,435,740 votes in favor, representing 99.9910% of the valid votes [7] - The proposal to expand the business scope, change registered capital, and amend the Articles of Association was also approved with 1,074,460,440 votes in favor, representing 99.9933% of the valid votes [8] Legal Opinion - The legal opinion provided by Zhejiang Tian Ce Law Firm confirms that the meeting's convening and voting procedures comply with relevant laws and regulations, and the voting results are valid [9] Stock Repurchase Announcement - The company plans to repurchase and cancel a total of 284,200 shares of restricted stock at a price of 22.85 yuan per share, funded by the company's own resources [12] - Following the repurchase, the total number of shares will decrease from 1,754,021,048 to 1,753,736,848, and the registered capital will reduce from 1,754,021,048 yuan to 1,753,736,848 yuan [13]

Meeting Information - The meeting was held on December 9, 2025, at 14:00 in Hangzhou, Zhejiang Province, at the new building of East China Pharmaceutical Co., Ltd. [3] - The meeting was conducted through a combination of on-site and online voting [4] Attendance - A total of 526 shareholders attended the meeting, representing 1,074,532,240 shares, which is 61.2611% of the total voting shares [5] - Among them, 524 minority shareholders participated, representing 55,594,083 shares, or 3.1695% of the total voting shares [6] Proposal Voting Results - The proposal to repurchase and cancel part of the restricted stock was approved with 1,074,435,740 shares in favor, accounting for 99.9910% of the valid votes [7] - Minority shareholders voted 55,497,583 shares in favor, representing 99.8264% of the valid votes [9] - The proposal to expand the business scope and amend the registered capital was also approved with 1,074,460,440 shares in favor, which is 99.9933% of the valid votes [10] - Minority shareholders voted 55,522,283 shares in favor, representing 99.8708% of the valid votes [11] Legal Opinion - The legal opinion from Zhejiang Tianche Law Firm confirmed that the meeting's procedures and voting were in compliance with relevant laws and regulations [12] Share Capital Changes - Following the repurchase, the total number of shares will decrease from 1,754,021,048 to 1,753,736,848 shares, and the registered capital will reduce from 1,754,021,048 yuan to 1,753,736,848 yuan [15]

证券代码：000963 证券简称：华东医药 公告编号：2025-112 华东医药股份有限公司 关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、通知债权人的原因 华东医药股份有限公司（以下简称"公司"） 于2025年11月20日 召开的第十一届董事会第五次会议审议通过了《关于回购注销部分限 制性股票的议案》，并于2025年12月09日召开2025年第二次临时股东 会，审议通过了《关于回购注销部分限制性股票的议案》，对首次授 予激励对象中6名因离职不再具备激励资格的激励对象、16名因第三 个解除限售期个人层面绩效考核结果为不合格的激励对象、3名因第 三个解除限售期个人层面绩效考核结果为合格的激励对象及预留授 予激励对象中1名因离职不再具备激励资格的激励对象、2名因第二个 解除限售期个人层面绩效考核结果为不合格的激励对象，对应的已获 授但尚未解除限售的限制性股票合计28.42万股进行回购注销。回购 价格为22.85元/股，回购资金来源为公司自有资金。 债权申报所需材料： 公司债权人可持证明债权债务关系存 ...

法律意见书 浙江天册律师事务所 关于 华东医药股份有限公司 2025 年第二次临时股东会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于华东医药股份有限公司 2025 年第二次临时股东会的 法律意见书 编号：TCYJS2025H2096 号 致：华东医药股份有限公司 （一）经本所律师核查，公司本次股东会由董事会提议并召集，召开本次股东 会的通知已于 2025 年 11 月 22 日在指定媒体及深圳证券交易所网站上公告。 （二）本次股东会采取现场投票与网络投票相结合的方式。 1 法律意见书 根据本次股东会的会议通知，本次股东会现场会议召开的时间为 2025 年 12 月 9 日下午 14:00；召开地点为浙江省杭州市拱墅区莫干山路 858 号华东医药股份有 限公司新大楼 3 楼三潭印月会议室。经本所律师的审查，本次股东会现场会议召 开的实际时间、地点与本次股东会的会议通知中所告知的时间、地点一致。 浙江天册律师事务所（以下简称"本所"）接受华东医药股份有限公司（以下 简 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无否决提案情形，也不涉及变更以往股东会已通 过决议的情形； 2、本次股东会对中小股东单独计票。中小股东是指：除公司董 事、高级管理人员以及单独或合计持有公司5%以上股份的股东以外 的其他股东。 一、会议召开情况 1、现场会议召开时间：2025年12月09日（星期二）下午14:00 证券代码：000963 证券简称：华东医药 公告编号：2025-111 华东医药股份有限公司 2025年第二次临时股东会决议公告 其中：通过现场投票的股东11人，代表股份1,020,331,667股，占 公司有表决权股份总数的58.1710%。 通过网络投票的股东515人，代表股份54,200,573股，占公司有表 决权股份总数的3.0901%。 2、中小股东出席的总体情况： 2、召开地点：浙江省杭州市拱墅区莫干山路858号华东医药股份 有限公司新大楼3楼三潭印月会议室。 3、召开方式：现场投票与网络投票相结合的表决方式 4、召集人：公司董事会 5、主持人：公司董事长 吕梁 6、本次会议召集、召开与表决程序符合 ...

Group 1 - The report highlights the recent increase in prices of isooctanol and sulfuric acid, indicating a potential shift in the chemical industry dynamics due to reduced capacity expansion globally, which may enhance cash flow and dividend yields for Chinese chemical companies [3][5][28] - The chromium salt industry is experiencing a value reassessment driven by increased demand from AI data centers and commercial aircraft engines, with a projected supply-demand gap of 340,900 tons by 2028, representing a 32% shortfall [5][6][28] - The report emphasizes the importance of domestic substitutes for Japanese semiconductor materials due to rising tensions in Sino-Japanese relations, suggesting a potential acceleration in domestic production capabilities [4][28] Group 2 - The report on Huadong Medicine indicates stable growth in its pharmaceutical segment, with a revenue increase of 3.77% year-on-year, and a net profit growth of 7.24% for the first three quarters of 2025 [29][30] - The innovative product sales and agency services of Huadong Medicine have significantly increased by 62%, with a notable contribution from the newly launched drug ELAHERE [31][32] - The company is focusing on expanding its innovative drug pipeline, with over 90 projects currently in development, and a substantial increase in R&D investment [31][32] Group 3 - The bond market analysis indicates a recent decline in long-term bonds, with a notable increase in the yield spread between 10Y and 30Y bonds, suggesting potential stabilization opportunities in the near term [33][34] - The report notes that the sentiment among bond market participants is shifting towards a more neutral stance, with a significant number of institutions adopting a wait-and-see approach amid economic uncertainties [40][41] - The report suggests that the current liquidity conditions remain favorable, which may support bond market performance in the upcoming period [34][35] Group 4 - The report discusses the acceleration of capacity reduction in the pig farming industry, with regulatory measures aimed at stabilizing pork prices, indicating a strategic focus on low-cost operations and potential value reassessment for leading companies in the sector [44][46] - The poultry sector is expected to improve, with a focus on the marginal changes in the market cycle, recommending investments in companies like Shengnong Development and Lihua Shares [45][46] - The report highlights the ongoing clinical trials for African swine fever vaccines, which could significantly impact the animal health sector and suggests monitoring developments in this area [46][47]

Core Viewpoint - Huadong Medicine (000963) has seen a slight increase in stock price and market capitalization, with recent announcements regarding the inclusion of its products in national medical insurance and commercial health insurance directories, which may benefit future market promotion but will not significantly impact recent performance [1]. Group 1: Stock Performance - As of December 8, 2025, Huadong Medicine's stock closed at 42.52 yuan, up 0.93% from the previous trading day [1]. - The stock opened at 42.58 yuan, reached a high of 43.07 yuan, and a low of 42.09 yuan, with a trading volume of 2.94 billion yuan and a turnover rate of 0.39% [1]. Group 2: Product Inclusion in Directories - On December 7, 2025, the National Healthcare Security Administration and other departments released a new version of the drug directory and commercial health insurance innovative drug directory [1]. - Huadong Medicine's subsidiary, Sino-American Huadong, has had its Ustinumab injection included in the regular directory management, with payment scope remaining unchanged [1]. - The company's cooperative products, Senapali capsules and Pentanedioic acid linaclotide capsules, have been included in the negotiated drug directory, while Zevokiorun injection has been added to the commercial insurance innovative drug directory [1]. - The new directory will take effect on January 1, 2026, and the inclusion of these products is expected to facilitate future market promotion, although it will not have a significant impact on the company's recent performance [1].

Core Viewpoint - The medical aesthetics industry is transitioning from scale expansion to quality enhancement, with compliance and standardization becoming critical paths for companies to break through [2][3]. Group 1: Current Status of Compliance in the Medical Aesthetics Industry - The medical aesthetics industry is at a critical juncture characterized by tightening regulations and ecological restructuring, with the market size reaching a trillion yuan [3]. - Issues such as "black institutions" and "black injectables" continue to hinder the healthy development of the industry, making compliance a necessity for survival rather than an option [3]. - Companies are collaborating to establish high-standard, transparent industry alliances, promoting initiatives like "tenfold compensation for counterfeit products" to enhance consumer trust [3]. Group 2: Role of Compliance in Industry Trust - Compliance is viewed not as a cost burden but as the best trust agent for the industry [4]. - The company, established in 2015, has built a direct sales system in 20 first-tier and new first-tier cities, focusing on technological upgrades and standard outputs to shift the industry from "marketing-driven" to "technology-driven" [4].

12月8日市场高开高走，截至收盘，沪指涨0.54%，深成指涨1.39%，创业板指涨2.6%。沪深两市成交额2.05万亿，较上一个交易日放量3127亿。全市场超 3400只个股上涨。 福建板块再度爆发，安记食品（603696）5连板，舒华体育（605299）、福建金森（002679）等10余股涨停。 算力硬件概念走强，天孚通信（300394）触及20cm涨停创新高，光库科技（300620）、长光华芯、源杰科技、联特科技（301205）等多股涨逾10%。一 共有17只股票涨停或涨幅超过10%。 中信建投（601066）认为，近期，AI产业链催化不断，包括谷歌新模型性能大幅提升及TPU展示出的较强能力、DeepSeek V3.2正式版发布、亚马逊发布 Trainium3，以及摩尔线程上市市场展现出的高参与热情等等，同时更多公司包括英伟达、阿里、AMD等否认AI泡沫的观点，均展现了AI的良好发展前 景。目前，世界正处于AI产业革命中，类比工业革命，影响深远，不能简单对比近几年的云计算、新能源等，需要以更长期的视角、更高的视野去观 察。因此，对AI带动的算力需求以及应用非常乐观。 消息面上，据智通财经，德银最新研报指出 ...

Market Performance - The market opened high on December 8, with the Shanghai Composite Index rising by 0.54%, the Shenzhen Component Index increasing by 1.39%, and the ChiNext Index up by 2.6% [1][2] - The total trading volume in the Shanghai and Shenzhen markets reached 2.05 trillion, an increase of 312.7 billion compared to the previous trading day, with over 3,400 stocks rising [1] Sector Highlights - The Fujian sector saw a significant surge, with Anji Food achieving five consecutive trading limits, and over ten stocks including Shuhua Sports and Fujian Jinsen hitting the daily limit [3] - The AI industry chain is experiencing continuous catalysis, with companies like Tianfu Communication and Guangpu Technology seeing stock prices rise over 10% [6] - The commercial aerospace concept remains strong, with Shunhao Co. achieving six trading limits in seven days, and Longzhou Co. hitting four consecutive limits [7] Pharmaceutical Sector - The pharmaceutical sector showed strong fluctuations, with multiple stocks rising over 10% following the announcement of the updated national medical insurance directory, which now includes 3,253 types of drugs [9][10] - Sixteen A-share listed pharmaceutical companies reported that their products were included in the national medical insurance directory or the innovative drug directory [10] Consumer Sector - In the Hong Kong market, consumer stocks experienced a downturn, with Pop Mart dropping nearly 9% and several related stocks declining over 3% [11] - Deutsche Bank noted that Pop Mart is increasing production capacity significantly, which may indicate a potential decline in brand heat due to mass production [12]